Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17557089 | 0.95 | TSHR (0.60) | TSHRMAPK1TDP1L3MBTL1MAPT | |
| SCHEMBL31499011 | 0.93 | TSHR (0.58) | TSHRMAPK1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7330639 | 0.93 | TSHR (0.58) | TSHRMAPK1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL1566399 | 0.93 | TSHR (0.58) | TSHRMAPK1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL9242647 | 0.89 | TSHR (0.56) | TSHRMAPK1TDP1L3MBTL1MAPT | |
| SCHEMBL31018801 | 0.86 | KDM4E (0.61) | TSHRMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL13239574 | 0.81 | TSHR (0.60) | TSHRMAPK1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL6790333 | 0.80 | TDP1 (0.71) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4351612 | 0.80 | TDP1 (0.66) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7431247 | 0.80 | TSHR (0.56) | TSHRMAPK1TDP1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262819-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | Beam Therapeutics Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2022140252-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11034994-B2 | In vivo detection of phospholipase activation | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | Apros Therapeutics, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190314372-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2019-10-17 | — | — | US | disclosed |
| EP-3548478-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9957546-B2 | Vivo detection of phospholipase activation | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-05-01 | — | — | US | disclosed |
| EP-1973583-B1 | PREPARATION OF AN INORGANIC SUBSTRATE HAVING ANTIMICROBIAL PROPERTIES | CENTRE NAT RECH SCIENT (FR) | 2016-09-14 | — | — | EP | disclosed |
| US-20110165084-A1 | VIVO DETECTION OF PHOSPHOLIPASE ACTIVATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-07-07 | — | — | US | disclosed |
| WO-2009111439-A2 | IN VIVO DETECTION OF PHOSPHOLIPASE ACTIVATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-1973583-A1 | PREPARATION OF AN INORGANIC SUBSTRATE HAVING ANTIMICROBIAL PROPERTIES | Centre National de la Recherche Scientifique (FR) | 2008-10-01 | — | — | EP | disclosed |
| EP-1902078-A1 | (METH)ACRYLAMIDE PHOSPHORUS MONOMER COMPOSITION | Ciba Specialty Chemicals Holding, Inc. (CH) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007080291-A1 | PREPARATION OF AN INORGANIC SUBSTRATE HAVING ANTIMICROBIAL PROPERTIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007006648-A1 | (METH)ACRYLAMIDE PHOSPHORUS MONOMER COMPOSITION | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2005080406-A2 | COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF | JERINI AG (DE) | 2005-09-01 | — | — | WO | disclosed |
| WO-1995031572-A1 | AMINOHYDROCARBON PHOSPHONATE OLIGONUCLEOTIDES AND USES THEREFOR | PHARMGENICS, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165084-A1 | VIVO DETECTION OF PHOSPHOLIPASE ACTIVATION | PLA2G4A, PLA2G4C, PLA2G4B | TSHR 3746/4885MAPK1 4420/4885TDP1 838/4885 |
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | TLR7, TLR9, STING1 | TSHR 3707/4885MAPK1 1816/4885TDP1 304/4885 |
| US-20190314372-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | TSHR 3962/4885MAPK1 2570/4885TDP1 312/4885 |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | LIPA, SGMS1, SGMS2 | TSHR 4628/4885MAPK1 4677/4885TDP1 3955/4885 |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | TSHR 3285/4885MAPK1 740/4885TDP1 388/4885 |
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | TSHR 3285/4885MAPK1 740/4885TDP1 388/4885 |
| US-11034994-B2 | In vivo detection of phospholipase activation | PLA2G4A, PLA2G4C, PLA2G4B | TSHR 3764/4885MAPK1 4485/4885TDP1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.